People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avenzo Therapeutics, Inc. | — | Biotechnology | Series D+ | $270.6M | $355.7M | 2022 |
Scott Lipman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott Lipman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Judith Li | 1 | 8 |
| Simeon George | 1 | 8 |
| Michael Rome | 1 | 3 |
| Garry Nicholson | 1 | 3 |
| Patrick Machado | 1 | 3 |
| Mohammad Hirmand | 1 | 2 |
| Athena Countouriotis | 1 | 2 |
| Brian Sun | 1 | 1 |
| Jakob Dupont, M.D., M.A. | 1 | 1 |
| Paolo Tombesi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.